Related Experiment Video

Updated: Jan 30, 2026

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma
08:18

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma

Published on: September 8, 2021

3.4K

Encorafenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF mutations

Claudia Trojaniello1, Lucia Festino1, Vito Vanella1

  • 1a Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics , Istituto Nazionale Tumori IRCCS Fondazione G. Pascale , Napoli , Italy.

Expert Review of Clinical Pharmacology
|January 18, 2019
PubMed
Abstract

Insights

Encorafenib plus binimetinib shows improved overall survival and progression-free survival for advanced BRAF-positive melanoma patients. This combination offers a promising alternative to existing BRAF/MEK inhibitor treatments.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • BRAF inhibitor and MEK inhibitor combination therapy is standard for advanced BRAFV600 mutation-positive melanoma.
  • Current combinations achieve over 12 months median progression-free survival (PFS).
  • Treatment resistance and disease recurrence remain significant clinical challenges.

Purpose of the Study:

  • To evaluate encorafenib in combination with binimetinib as a novel therapeutic approach for advanced BRAF-positive melanoma.
  • To compare the efficacy and tolerability of encorafenib/binimetinib against existing BRAF/MEK inhibitor combinations.

Main Methods:

  • Phase III COLUMBUS trial.
  • Assessment of overall survival (OS) and progression-free survival (PFS).
  • Pharmacokinetic analysis of encorafenib and evaluation of side effect profiles.

Main Results:

  • Encorafenib plus binimetinib achieved a median OS of 33.6 months, surpassing existing combinations.
  • Improved PFS was observed with encorafenib plus binimetinib.
  • Encorafenib's distinct pharmacokinetics suggest enhanced BRAF inhibition and potency.
  • Potentially better tolerability with reduced pyrexia and photosensitivity compared to other agents.

Conclusions:

  • Encorafenib plus binimetinib represents a valuable therapeutic option for advanced BRAF-positive melanoma.
  • The combination demonstrates improved efficacy and potentially better tolerability.
  • This regimen may emerge as a preferred alternative to current BRAF/MEK inhibitor standards of care.
Keywords:
inhibitorBinimetinibencorafenibmelanomatargeted therapy

More Related Videos

Injection of Syngeneic Murine Melanoma Cells to Determine Their Metastatic Potential in the Lungs07:31

Injection of Syngeneic Murine Melanoma Cells to Determine Their Metastatic Potential in the Lungs

Published on: May 24, 2016

18.2K
A Melanoma Patient-Derived Xenograft Model07:07

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

13.2K

Related Concept Videos

Mutations01:39

Mutations

Overview
94.5K
Mutations01:35

Mutations

Mutations are changes in the sequence of DNA. These changes can occur spontaneously or they can be induced by exposure to environmental factors. Mutations can be characterized in a number of different ways: whether and how they alter the amino acid sequence of the protein, whether they occur over a small or large area of DNA, and whether they occur in somatic cells or germline cells.
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
44.5K
Viral Mutations00:36

Viral Mutations

A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material...
39.9K
Mutation, Gene Flow, and Genetic Drift01:09

Mutation, Gene Flow, and Genetic Drift

In a population that is not at Hardy-Weinberg equilibrium, the frequency of alleles changes over time. Therefore, any deviations from the five conditions of Hardy-Weinberg equilibrium can alter the genetic variation of a given population. Conditions that change the genetic variability of a population include mutations, natural selection, non-random mating, gene flow, and genetic drift (small population size).
64.2K
Mutations in Microorganisms01:18

Mutations in Microorganisms

Mutations are heritable changes in an organism’s genome involving alterations in the base sequence of DNA or RNA. These changes can influence cellular processes and phenotypic traits, potentially transforming the unaltered wild type into a mutant form. Such changes, termed forward mutations, are pivotal in shaping the genetic diversity of organisms.RNA viruses exhibit the highest mutation rates due to the absence of robust proofreading mechanisms during genome replication. In contrast,...
723
Point and Frameshift Mutations01:30

Point and Frameshift Mutations

Point mutations are genetic alterations involving the change of a single nucleotide base pair in DNA. Depending on how the alteration affects protein synthesis, they can lead to various consequences.Point mutations fall into the following types:Silent mutations occur when a nucleotide change does not alter the amino acid sequence due to the redundancy of the genetic code. For instance, changing ACC to ACA still encodes threonine, leaving the protein function unaffected. This occurs because...
1.2K